ImmunoCellular Therapeutics Ltd (NYSE MKT LLC:IMUC)

Delayed Data
As of Apr 24
 -0.0061 / -1.14%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

ImmunoCellular Therapeutics Ltd. is a clinical-stage biotechnology company, which focuses on developing immune-based therapies for the treatment of brain and other cancers. Its cell-based vaccine technologies are primary platform technologies and commercial prospects will be heavily dependent on the outcome of the contemplated clinical trials for current lead vaccine product candidate. Its product pipeline includes peptide based vaccine to target cancer stem cells, cellular immunotherapies to target cancer associated antigens, and monoclonal antibodies to diagnose and treat several different cancers. ImmunoCellular product candidates include ICT-107, CT-121, ICT-109, ICT-037, ICT-69 and CT-Diagnostic-SCLC. Its antibodies are designed to treat small cell lung cancer, pancreatic cancer, multiple myeloma and ovarian cancer. The company was founded on March 20, 1987 and is headquartered in Woodland Hills, CA.

Contact Information

ImmunoCellular Therapeutics Ltd.
23662 Calabasas Road
Calabasas California 91302
P:(818) 264-2300
Investor Relations:



Mutual fund holders3.72%
Other institutional15.87%
Individual stakeholders1.57%

Top Executives

John S. YuChairman, Secretary & Chief Scientific Officer
Andrew GengosPresident, Chief Executive Officer & Director
Steven J. SwansonSenior Vice President-Research
Anthony J. GringeriSenior Vice President-Strategic Resources
David E. FractorTreasurer, Chief Accounting Officer & VP-Finance

To view my watchlist

Not a member yet?

Sign up now for a free account